Yervoy (ipilimumab) / BMS 
Welcome,         Profile    Billing    Logout  
 197 Diseases   398 Trials   398 Trials   21826 News 


«12...4546474849505152535455...266267»
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Enrollment change, Trial completion date, Trial primary completion date, Checkpoint inhibition:  Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (clinicaltrials.gov) -  Mar 30, 2023   
    P1,  N=10, Active, not recruiting, 
    Trial completion date: Dec 2023 --> May 2022 | Active, not recruiting --> Terminated; Sponsor closed study N=16 --> 10 | Trial completion date: May 2023 --> Mar 2024 | Trial primary completion date: May 2023 --> Oct 2022
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    TRIPLE WHAMMY WITH IMMUNE CHECKPOINT INHIBITOR THERAPY: A CASE REPORT () -  Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_657;    
    Conclusions Three different renal pathologies in a single patient treated with ICI is rare and portends a poor response to treatment. Renal infarction needs to be considered as a differential in patients with AKI on ICI therapy and history of thrombophilia.
  • ||||||||||  Opdivo (nivolumab) / BMS, pexmetinib (ARRY-614) / Pfizer, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date:  Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab (clinicaltrials.gov) -  Mar 28, 2023   
    P1/2,  N=144, Recruiting, 
    Further international studies are required to define the optimal strategies for managing unresectable or metastatic cHCC-CCA. Trial completion date: Jun 2024 --> Jun 2027 | Trial primary completion date: Mar 2023 --> Mar 2026
  • ||||||||||  izuralimab (XmAb23104) / Xencor
    Trial completion date, Trial primary completion date, Metastases:  A Study of XmAb (clinicaltrials.gov) -  Mar 28, 2023   
    P1,  N=300, Recruiting, 
    Trial completion date: Jun 2024 --> Jun 2027 | Trial primary completion date: Mar 2023 --> Mar 2026 Trial completion date: Dec 2024 --> Sep 2025 | Trial primary completion date: Jul 2023 --> Dec 2024
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Checkpoint inhibition:  Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC (clinicaltrials.gov) -  Mar 27, 2023   
    P1/2,  N=9, Terminated, 
    Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Feb 2023 --> Feb 2024 N=57 --> 9 | Trial completion date: Oct 2025 --> Mar 2023 | Recruiting --> Terminated | Trial primary completion date: Oct 2024 --> Mar 2023; DLTs
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    P2 data, Clinical Trial,Phase II, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases:  Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-na (Pubmed Central) -  Mar 25, 2023   
    P2
    Each treatment has a unique specific toxicity profile, which needs more attention. Nivolumab monotherapy has limited activity in treatment-na
  • ||||||||||  A Radiation Recall Pneumonitis From Immune Checkpoint Inhibitors After Extra Pulmonary Radiation (Walter E. Washington Convention Center, Area D, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_7384;    
    Case 3 is a 68-year-old man with renal clear cell carcinoma and epidural disease, treated with radiation to T6 vertebrae, followed by nivolumab and ipilimumab...Irradiation can induce both acute and long-term pulmonary toxicities. Lung parenchyma, which has not reached inflammatory pneumonitis threshold, can be reactivated with subsequent ICI treatment, creating an additive effect to local inflammation, hitting the threshold for clinically detected pneumonitis.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Immunotherapy Related New-onset Type 1 Diabetes Mellitus and DKA (Walter E. Washington Convention Center, Area I, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_6603;    
    Clinicians must be aware of DKA as a potentially fatal adverse event of immunotherapy. Risk versus benefits needs to be considered in a cancer patient that needs life-saving immunotherapy.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Fish Out of Water: A Rare Case of Metastatic Disease Presenting as Endobronchial Obstruction (Walter E. Washington Convention Center, Area L, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_5813;    
    Patients usually present with multiple metastatic organ involvement and nonspecific clinical presentation. Our case highlights the possibility of endobronchial obstruction in patients with metastatic melanoma which may require palliative laser embolization to prevent aspiration and improve the quality of end-of-life care in the absence of curative options available.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Yervoy (ipilimumab) / Ono Pharma, BMS
    A Rare Case of Immune Checkpoint Inhibitor Induced Tracheitis (Walter E. Washington Convention Center, Area L, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_5811;    
    We present a novel case of a patient who likely developed immunotherapy-induced tracheitis.Description of case report: A sixty-three-year-old male with a history of cutaneous melanoma status post surgical resection and axillary lymph node dissection currently on Pembrolizumab and ??Ipilimumab, oropharyngeal squamous cell carcinoma status post total laryngectomy and radiation therapy, pulmonary vein thrombosis (on Apixaban) and former tobacco user (45 pack year history) presented with a six-week nocturnal productive cough that was blood-tinged. However, the patient
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    A Rare Case of Isolated Pulmonary Melanoma (Walter E. Washington Convention Center, Area L, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_5806;    
    Surgical management of stage III MUP had also been shown to produce a better outcome compared with nonsurgical management. However, data comparing surgical versus nonsurgical management on MUP of stage IV is lacking.
  • ||||||||||  Yervoy (ipilimumab) / Ono Pharma, BMS
    Immune Checkpoint Blockade Is Associated With Improved Alveolar Epithelial Repair Responses in a Humanized CTLA4 Murine Model (Walter E. Washington Convention Center, Room 202 B (Level 2)) -  Mar 25, 2023 - Abstract #ATS2023ATS_3932;    
    Immune checkpoint inhibition increases the AT2 cell population and associated markers of alveolar epithelial regeneration. We also report increased number of Cd3+ T cells with Iplimumab treatment, supporting a role for CTLA4 targeting of cytotoxic T cells to accelerate clearance of senescent T cells in this murine lung injury model.
  • ||||||||||  Retrospective data, Review, Journal:  Recent advances in the molecular targeted drugs for prostate cancer. (Pubmed Central) -  Mar 24, 2023   
    With the approval of a variety of targeted drugs, targeted therapy will be widely used in the treatment of advanced or metastatic prostate cancer. Despite the existence of adverse reactions related to targeted drug treatment, it is still meaningful to adjust the drug dosage or treatment cycle to reduce the occurrence of adverse reactions, improving the treatment benefits of patients.
  • ||||||||||  Journal, PD(L)-1 Biomarker, IO biomarker:  Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy. (Pubmed Central) -  Mar 24, 2023   
    Immune checkpoint inhibitors were significantly associated with transplant rejection in SOTRs. The presented case of sarcomatoid UC of the renal pelvis that partially responded to immunotherapy suggests that immunotherapy can be a promising treatment for sarcomatoid UC.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    IMMUNOMODULATORS FOR STEROID-DEPENDENT RECURRENT ACUTE PANCREATITIS AFTER IMMUNE CHECKPOINT INHIBITOR: A CASE SERIES (S502 - McCormick Place) -  Mar 23, 2023 - Abstract #DDW2023DDW_6054;    
    Case Description: Case 1: A 67-year-old female with metastatic lung adenocarcinoma who was on pemetrexed and pembrolizumab infusions every 3 weeks for the past year...She was started on azathioprine (AZA) along with high-dose prednisone...She was switched to mycophenolate mofetil (MMF) and titrated up to 2000 mg/day...Case 2: A 53-year-old female with metastatic fibrosarcoma was started on nivolumab and ipilimumab...She was switched to mycophenolate sodium and titrated to 720 mg BID...Immunomodulators have their own set of unique adverse events which requires careful monitoring. Further studies are needed to validate its effectiveness and use.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    LENGTH OF STEROID TREATMENT FOR IMMUNE-CHECKPOINT INHIBITOR COLITIS ASSOCIATED WITH REDUCED CANCER RESPONSE (South Hall A, Poster Hall - McCormick Place) -  Mar 23, 2023 - Abstract #DDW2023DDW_2498;    
    In this large series of cancer patients developing ICIC we demonstrate that most patients experienced a median of 80 days of symptoms frequently treated with systemic steroids, and 56% never restarted ICI. Duration of systemic steroid therapy was associated with reduced cancer response, and higher-grade colitis was associated with mortality.
  • ||||||||||  IMMUNE-RELATED ADVERSE EVENTS FOLLOWING IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (ePoster - DDW Online Platform) -  Mar 23, 2023 - Abstract #DDW2023DDW_639;    
    Of the included patients, 8,582 (1.7%) patients received ICIs, whereas 496,709 (98.3%) did not receive ICIs. Within one year follow-up, patients who received ICIs was associated with increased new onset immune-related side effects, including hypopituitarism (HR, 7.31; 95% CI, 4.49-11.92, P<0.01), hypothyroidism (HR, 6.18; 95% CI, 5.65-6.76, P<0.01), hyperthyroidism (HR, 5.55; 95% CI, 4.56-6.75, P<0.01), Cushing syndrome (HR, 2.81; 95% CI, 1.39-5.72, P<0.01), myocarditis (HR, 4.68; 95% CI, 3.11-7.03, P<0.01), pneumonitis (HR, 2.16; 95% CI, 1.83-2.55, P< 0.01), pleural plaque (HR, 6.19; 95% CI, 4.92-7.79, P<0.01), pleural effusion (HR, 3.60; 95% CI, 3.10-4.19, P<0.01), ulcerative colitis (HR, 2.38; 95% CI, 1.66-3.41, P<0.01), Crohn's disease (HR, 1.79; 95% CI, 1.25-2.56, P<0.01), gastroenteritis (HR, 3.50; 95% CI, 3.17-3.86, P<0.01), vitiligo (HR, 3.90; 95% CI, 2.62-5.80, P<0.01) and primary adrenal insufficiency (HR, 7.61; 95% CI, 5.21-11.12, P<0.01).
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date:  CYTOSHRINK: SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (clinicaltrials.gov) -  Mar 23, 2023   
    P2,  N=78, Recruiting, 
    Overall, the incidence of irAE was greater in patients who received ICIs (HR, 2.75; 95% CI, 2.54-2.99, P<0.01). Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2022 --> Mar 2024
  • ||||||||||  Opdivo (nivolumab) / BMS
    Trial completion date, Trial primary completion date, IO biomarker:  BELLINI: Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO (clinicaltrials.gov) -  Mar 23, 2023   
    P2,  N=80, Recruiting, 
    Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2022 --> Mar 2024 Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Jan 2023 --> Jan 2025